Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 8INDUSTRY 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Neoplasms 67Lymphoma 55Multiple Myeloma 53Breast Neoplasms 52Neoplasm Metastasis 47Lung Neoplasms 47Prostatic Neoplasms 46Ovarian Neoplasms 39Leukemia, Myeloid, Acute 39Melanoma 37Carcinoma, Non-Small-Cell Lung 37Hematologic Neoplasms 35Colorectal Neoplasms 32Pancreatic Neoplasms 29Glioma 28Lymphoma, Non-Hodgkin 26Urinary Bladder Neoplasms 25Sarcoma 25Carcinoma, Renal Cell 25Brain Neoplasms 23Myelodysplastic Syndromes 21Neuroblastoma 20Triple Negative Breast Neoplasms 19Fallopian Tube Neoplasms 19Stomach Neoplasms 18Leukemia, Lymphocytic, Chronic, B-Cell 18Small Cell Lung Carcinoma 17Colonic Neoplasms 17Burkitt Lymphoma 17Glioblastoma 16

Interventions

pembrolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Diffusion Tensor Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Turcot syndrome × 90 days × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡